ANANYA MUNJAL
COLUMBIA, SC NPI 1972208353
Browse related groups: SC Janssen Pharmaceuticals, Inc All categories
General Payments — all program years on this page
$996.06
- Category: General Payments
- Program years: PY2024
- Record count: 8
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $996.06 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $996.06 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $146.24 | 1 |
| Neurocrine BioSciences, Inc. | $128.77 | 1 |
| ABBVIE INC. | $124.80 | 1 |
| ITI, Inc. | $123.23 | 1 |
| Sight Sciences, Inc. | $120.56 | 1 |
| Vanda Pharmaceuticals Inc. | $118.15 | 1 |
| Otsuka America Pharmaceutical, Inc. | $117.77 | 1 |
| E.R. Squibb & Sons, L.L.C. | $116.54 | 1 |
By program year
| Program year | Amount | Records |
|---|---|---|
| 2024 | $996.06 | 8 |
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078175631 | Janssen Pharmaceuticals, Inc | $146.24 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1101348458 | E.R. Squibb & Sons, L.L.C. | $116.54 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105082271 | ABBVIE INC. | $124.80 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118947267 | Otsuka America Pharmaceutical, Inc. | $117.77 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133913782 | Vanda Pharmaceuticals Inc. | $118.15 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1143283240 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123.23 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150808406 | Neurocrine Biosciences, Inc. | $128.77 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151922146 | Sight Sciences, Inc. | $120.56 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.